PMID- 33795183
OWN - NLM
STAT- MEDLINE
DCOM- 20230714
LR  - 20230718
IS  - 1873-4588 (Electronic)
IS  - 0892-1997 (Linking)
VI  - 37
IP  - 4
DP  - 2023 Jul
TI  - Chronic Course, Weaning, and Awareness of Patients With Reflux Toward Proton Pump 
      Inhibitor Therapy.
PG  - 578-585
LID - S0892-1997(21)00098-9 [pii]
LID - 10.1016/j.jvoice.2021.03.002 [doi]
AB  - OBJECTIVES: To assess the feasibility of middle-term proton pump inhibitor (PPI) 
      weaning in patients with laryngopharyngeal reflux (LPR) and evaluate patient 
      awareness of PPI adverse events. METHODS: We conducted a cross-sectional study of 
      100 LPR patients treated with an association of diet, PPIs, and alginate. 
      Patients were followed from September 2016 to May 2020. At the end of the initial 
      3-to-6 months therapeutic period, LPR patients were weaned from PPIs and 
      instructed to respect diet and stress management over the long-term. The 3-year 
      symptom recurrence rate, PPI use, and patient awareness of PPI adverse events 
      were assessed. RESULTS: Sixty-seven patients completed the evaluation. 
      Twenty-seven patients (40.3%) reported a chronic course of LPR-symptoms, 
      requiring chronic or occasional PPI use. LPR symptom recurrence occurred 1-to-2 
      or 3-to-5 times yearly in 8.9% and 20.9% of patients, respectively. Recurrences 
      were managed by short-term diet, alginate, or PPI intake. The remaining patients 
      (29.9%) did not report middle-term LPR recurrence. The 3-year weaning rate of 
      occasional or chronic use of PPIs was 64.2%. Among participants, 26.8% were aware 
      of PPI-related adverse events, most frequently through physicians (33%), online 
      sources (17%), and friends or family (17%). Nonresponder patients were 
      significantly more aware of PPI adverse events than responders (P = 0.029). 
      PPI-attributed adverse events occurred in 29.8% of patients. CONCLUSION: 
      Sixty-four percent of LPR patients treated with PPIs were weaned at 3-year 
      posttreatment time. Different forms of LPR may exist regarding symptom relief, 
      recurrences, and chronic course.
CI  - Copyright (c) 2021 The Voice Foundation. Published by Elsevier Inc. All rights 
      reserved.
FAU - Verhasselt, Marie
AU  - Verhasselt M
AD  - Department of Otolaryngology-Head & Neck Surgery, CHU de Bruxelles, CHU 
      Saint-Pierre, Universite Libre de Bruxelles, Brussels, Belgium.
FAU - Rodriguez, Alejandra
AU  - Rodriguez A
AD  - Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, Paris Saclay 
      University, Paris, France.
FAU - Dequanter, Didier
AU  - Dequanter D
AD  - Department of Human Anatomy and Experimental Oncology, University of Mons, Mons, 
      Belgium.
FAU - Lechien, Jerome R
AU  - Lechien JR
AD  - Department of Otolaryngology-Head & Neck Surgery, CHU de Bruxelles, CHU 
      Saint-Pierre, Universite Libre de Bruxelles, Brussels, Belgium. Electronic 
      address: Jerome.Lechien@umons.ac.be.
LA  - eng
PT  - Journal Article
DEP - 20210330
PL  - United States
TA  - J Voice
JT  - Journal of voice : official journal of the Voice Foundation
JID - 8712262
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Humans
MH  - *Proton Pump Inhibitors/adverse effects
MH  - Cross-Sectional Studies
MH  - Weaning
MH  - *Laryngopharyngeal Reflux/diagnosis/drug therapy/complications
MH  - Recurrence
OTO - NOTNLM
OT  - Reflux-Laryngopharyngeal- Proton pump inhibitor-Adverse event- 
      Interaction-Patients-Treatment-Therapy
EDAT- 2021/04/03 06:00
MHDA- 2023/07/14 13:07
CRDT- 2021/04/02 05:51
PHST- 2020/11/14 00:00 [received]
PHST- 2021/02/22 00:00 [revised]
PHST- 2021/03/01 00:00 [accepted]
PHST- 2023/07/14 13:07 [medline]
PHST- 2021/04/03 06:00 [pubmed]
PHST- 2021/04/02 05:51 [entrez]
AID - S0892-1997(21)00098-9 [pii]
AID - 10.1016/j.jvoice.2021.03.002 [doi]
PST - ppublish
SO  - J Voice. 2023 Jul;37(4):578-585. doi: 10.1016/j.jvoice.2021.03.002. Epub 2021 Mar 
      30.